Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998 Jan;11(1):142-201.
Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004 Feb;2(2):123-40.
Easton L. Escherichia coli O157: occurrence, transmission and laboratory detection. Br J Biomed Sci. 1997 Mar;54(1):57-64.
American Medical Association; American Nurses Association-American Nurses Foundation; Centers for Disease Control and Prevention; Center for Food Safety and Applied Nutrition, Food and Drug Administration; Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep. 2004 Apr 16;53(RR-4):1-33.
King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003 Nov 21;52(RR-16):1-16.
World Health Organization. Foodborne disease outbreaks: guidelines for investigation and control. Geneva: WHO Press; 2008.
Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006 Sep 1;24(5):731-42.
1. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998 Jan;11(1):142-201.
2. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004 Feb;2(2):123-40.
3. Garcia-Aljaro C, Momba M, Muniesa M; Global Water Pathogen Project. Pathogenic members of Escherichia coli & Shigella spp. Shigellosis. August 2018 [internet publication].
4. Orskov F, Orskov I. Escherichia coli serotyping and disease in man and animals. Can J Microbiol. 1992 Jul;38(7):699-704.
5. Marder EP, Griffin PM, Cieslak PR, et al. Preliminary incidence and trends of infections with pathogens transmitted commonly through food: Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2006-2017. MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):324-8.
6. Ochoa TJ, Contreras CA. Enteropathogenic escherichia coli infection in children. Curr Opin Infect Dis. 2011 Oct;24(5):478-83.
7. Lanata CF, Mendoza W; World Health Organization. Improving diarrhoea estimates. October 2002 [internet publication].
8. Ahmed T, Bhuiyan TR, Zaman K, et al. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev. 2013 Jul 5;(7):CD009029.
9. Steffen R, Castelli F, Dieter Nothdurft H, et al. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med. 2005 Mar-Apr;12(2):102-7.
10. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009 Apr;80(4):609-14.
11. Ochoa TJ, Barletta F, Contreras C, et al. New insights into the epidemiology of enteropathogenic Escherichia coli infection. Trans R Soc Trop Med Hyg. 2008 Sep;102(9):852-6.
12. Centers for Disease Control and Prevention. E. coli (Escherichia coli): questions and answers. February 2018 [internet publication].
13. Rangel JM, Sparling PH, Crowe C, et al. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg Infect Dis. 2005 Apr;11(4):603-9.
14. Centers for Disease Control and Prevention. Multistate outbreak of E.coli O157:H7 infections linked to romaine lettuce (final update). June 2018 [internet publication].
15. Centers for Disease Control and Prevention. Outbreak of E. coli infections linked to romaine lettuce. January 2019 [internet publication].
16. Meraz IM, Jiang ZD, Ericsson CD, et al. Enterotoxigenic Escherichia coli and diffusely adherent E coli as likely causes of a proportion of pathogen-negative travelers' diarrhea: a PCR-based study. J Travel Med. 2008 Nov-Dec;15(6):412-8.
17. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25.
18. Easton L. Escherichia coli O157: occurrence, transmission and laboratory detection. Br J Biomed Sci. 1997 Mar;54(1):57-64.
19. Ahmad A, Nagaraja TG, Zurek L. Transmission of Escherichia coli O157:H7 to cattle by house flies. Prev Vet Med. 2007 Jun 15;80(1):74-81.
20. David ST, MacDougall L, Louie K, et al. Petting zoo-associated Escherichia coli O157:h7 - secondary transmission, asymptomatic infection, and prolonged shedding in the classroom. Can Commun Dis Rep. 2004 Oct 15;30(20):173-80.
21. Ojeniyi AA. Direct transmission of Escherichia coli from poultry to humans. Epidemiol Infect. 1989 Dec;103(3):513-22.
22. Erb A, Sturmer T, Marre R, et al. Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations. Eur J Clin Microbiol Infect Dis. 2007 Feb;26(2):83-90.
23. White DG, Zhao S, Simjee S, et al. Antimicrobial resistance of foodborne pathogens. Microbes Infect. 2002 Apr;4(4):405-12.
24. Beatty ME, Adcock PM, Smith SW, et al. Epidemic diarrhea due to enterotoxigenic Escherichia coli. Clin Infect Dis. 2006 Feb 1;42(3):329-34.
25. Damborg P, Nielsen SS, Guardabassi L. Escherichia coli shedding patterns in humans and dogs: insights into within-household transmission of phylotypes associated with urinary tract infections. Epidemiol Infect. 2009 Oct;137(10):1457-64.
26. Käferstein FK, Motarjemi Y, Bettcher DW. Foodborne disease control: a transnational challenge. Emerg Infect Dis. 1997 Oct-Dec;3(4):503-10.
27. Schlundt J. New directions in foodborne disease prevention. Int J Food Microbiol. 2002 Sep 15;78(1-2):3-17.
28. American Medical Association; American Nurses Association-American Nurses Foundation; Centers for Disease Control and Prevention; Center for Food Safety and Applied Nutrition, Food and Drug Administration; Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep. 2004 Apr 16;53(RR-4):1-33.
29. Centers for Disease Control and Prevention. Yellow book: chapter 2 - travelers' diarrhea. June 2017 [internet publication].
30. Scottish Infection Standards and Strategy Group. Guidance for the diagnosis and management of suspected or proven E. coli O157 infection. J R Coll Physicians Edinb. 2004;34(1):37-40.
31. Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of shiga toxin--producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep. 2009 Oct 16;58(RR-12):1-14.
32. King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003 Nov 21;52(RR-16):1-16.
33. Hartling L, Bellemare S, Wiebe N, et al. Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004390.
34. Dohi-Fujii B, Godoy-Olvera LM, Durazo-Ortiz J. Oral rehydration therapy: an analysis of its results and impact on the hospitalization and mortality of children with diarrhea [in Spanish]. Bol Med Hosp Infant Mex. 1993 Nov;50(11):797-802.
35. Slotwiner-Nie PK, Brandt LJ. Infectious diarrhea in the elderly. Gastroenterol Clin North Am. 2001 Sep;30(3):625-35.
36. Aranda-Michel J, Giannella RA. Acute diarrhea: a practical review. Am J Med. 1999 Jun;106(6):670-6.
37. World Health Organization. Children: reducing mortality. September 2018 [internet publication].
38. World Health Organization. Foodborne disease outbreaks: guidelines for investigation and control. Geneva: WHO Press; 2008.
39. Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med. 1993 Jun 10;328(23):1653-8.
40. Soriano-Brucher H, Avendano P, O'Ryan M, et al. Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study. Pediatrics. 1991 Jan;87(1):18-27.
41. Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea. Curr Med Res Opin. 1997;14(1):39-45.
42. Beseghi U, De'Angelis GL. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children. Eur Rev Med Pharmacol Sci. 1998 May-Aug;2(3-4):131-6.
43. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007 Feb 1;44(3):338-46.
44. Proulx F, Turgeon JP, Delage G, et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr. 1992 Aug;121(2):299-303.
45. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930-6.
46. Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med. 1987 Dec 10;317(24):1496-500.
47. Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006 Sep 1;24(5):731-42.
48. Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med. 1993 Apr 15;118(8):582-6.
49. Centers for Disease Control and Prevention. Yellow book: chapter 3 - Escherichia coli, diarrheagenic. May 2017 [internet publication].
50. Banks MR, Farthing MJ, Robberecht P, et al. Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine. Br J Pharmacol. 2005 Apr;144(7):994-1001.
51. Brüssow H. Phage therapy: the Escherichia coli experience. Microbiology. 2005 Jul;151(Pt 7):2133-40.
52. Mushtaq N, Redpath MB, Luzio JP, et al. Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase. J Antimicrob Chemother. 2005 Jul;56(1):160-5.
53. Smith DR, Moxley RA, Peterson RE, et al. A two-dose regimen of a vaccine against Escherichia coli O157:H7 type III secreted proteins reduced environmental transmission of the agent in a large-scale commercial beef feedlot clinical trial. Foodborne Pathog Dis. 2008 Oct;5(5):589-98.
54. Ahmed A, Li J, Shiloach Y, et al. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis. 2006 Feb 15;193(4):515-21.
55. Centers for Disease Control and Prevention. Burden of foodborne illness: findings. July 2016 [internet publication].
56. Dundas S, Todd WT, Stewart AI, et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis. 2001 Oct 1;33(7):923-31.
57. Tserenpuntsag B, Chang HG, Smith PF, et al. Hemolytic uremic syndrome risk and Escherichia coli O157:H7. Emerg Infect Dis. 2005 Dec;11(12):1955-7.
58. Begue RE, Mehta DI, Blecker U. Escherichia coli and the hemolytic-uremic syndrome. South Med J. 1998 Sep;91(9):798-804.
59. World Health Organization. Factsheet: E. coli. February 2018 [internet publication].
60. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44.
61. Acheson DW, Fiore AE. Preventing foodborne disease - what clinicians can do. N Engl J Med. 2004 Jan 29;350(5):437-40.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台